News

These data expanded upon limited real-world data on retention of dupilumab past 2 years of treatment for patients with atopic dermatitis.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

The FDA's approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.

Concizumab marks the first subcutaneous injection treatment for hemophilia A or B with inhibitors, demonstrating an 86% reduction in bleeds in pivotal trial data.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Patients with PSC had worse death, transplant, liver-related mortality, and liver-related decompensation outcomes than PBC and autoimmune hepatitis.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

In this case–control study, investigators identified relevant comorbidities among individuals with bullous pemphigoid before and after their diagnoses.

The ML model exhibited better predictive performance than previous traditional HCC models in patients with chronic HBV on long-term antiviral therapy.

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

Yehuda Handelsman, MD reflects on the WCIRDC 2024’s comprehensive approach to advancing cardiometabolic care through multidisciplinary collaboration.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

The phase 2b/3 NAVIGATE trial missed its primary endpoint for the prevention of varices in patients with MASH cirrhosis and portal hypertension.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.

These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Retransplantation outcomes were similar or better in patients with PSC compared with patients with other liver disease etiologies.

Olezarsen ushers in a new era of care as the first therapy to receive FDA approval for adults with familial chylomicronemia syndrome as an adjunct to diet.

Yehuda Handelsman, MD highlights insulin resistance’s role in cardiometabolic disease and introduces DCRM 2.0 as a global, multi-specialty care framework.

The VISIBLE study’s findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.